目的 探討地奧心血康膠囊聯(lián)合尼可地爾治療冠心病心肌缺血的療效。方法 選取天津市靜海區(qū)醫(yī)院在2015年7月-2016年7月收治的冠心病心肌缺血患者161例，隨機分成對照組（80例）和治療組（81例）。對照組口服尼可地爾片，1片/次，3次/d。治療組在對照組的基礎(chǔ)上口服地奧心血康膠囊，2粒/次，3次/d。兩組患者均規(guī)律治療6周。評價兩組患者臨床療效，同時比較治療前后兩組患者ST段壓低次數(shù)、心肌耗氧量和心肌缺血總負荷、N-末端腦鈉肽前體（NT-proBNP）水平和不良反應(yīng)差異。結(jié)果 治療后，對照組和治療組的總有效率分別為81.25%、97.53%；兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者ST段壓低次數(shù)、心肌耗氧量和心肌缺血總負荷均明顯降低（P<0.05）；且治療組這些指標均明顯低于對照組患者（P<0.05）。治療后，兩組NT-proBNP水平均顯著降低，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組NT-proBNP水平明顯低于對照組，兩者比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療期間，對照組不良反應(yīng)發(fā)生率為16.25%，顯著高于治療組的4.94%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 地奧心血康膠囊聯(lián)合尼可地爾治療冠心病心肌缺血具有顯著的臨床療效，可顯著改善患者心肌缺血的預(yù)后，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical efficacy of Di'ao Xinxuekang Capsules combined with nicorandil in treatment of myocardial ischemia of coronary heart disease. Methods Patients (161 cases) with myocardial ischemia of coronary heart disease in Jinghai Hospital of Tianjin from July 2015 to July 2016 were randomly divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were po administered with Nicorandil Tabltes, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Di'ao Xinxuekang Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the differences of ST segment depression times, myocardial oxygen consumption, total myocardial ischemia load, NT-proBNP levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.25% and 97.53%, respectively, and there were differences between two groups (P<0.05). After treatment, the ST segment depression time, myocardial oxygen consumption and total myocardial ischemia load in two groups were significantly decreased (P<0.05). These indicators in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the NT-proBNP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the NT-proBNP level in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the incidence of adverse reaction in the control group was 16.25%, which was significantly higher than 4.94% in the treatment group, and there were differences between two groups (P<0.05). Conclusion Di'ao Xinxuekang Capsules combined with nicorandil have significant clinical efficacy in treatment of myocardial ischemia of coronary heart disease, and can significantly improve the prognosis of myocardial ischemia, which has a certain clinical application value.